Hosted on MSN18h
BridgeBio Oncology and Helix enter definitive merger agreement
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
Hosted on MSN13h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer Drugs
Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
The Pharma Letter21h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
BioPharma Dive1h
Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda
Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...
BioPharma Dive19h
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...